A Randomized Trial of AmBisome Monotherapy and AmBisome and Miltefosine Combination to Treat Visceral leishmaniasis in HIV Co-infected Patients in Ethiopia

Hdl Handle:
http://hdl.handle.net/10144/619327
Title:
A Randomized Trial of AmBisome Monotherapy and AmBisome and Miltefosine Combination to Treat Visceral leishmaniasis in HIV Co-infected Patients in Ethiopia
Authors:
Diro, E; Blesson, S; Edwards, T; Ritmeijer, K; Fikre, H; Admassu, H; Kibret, A; Ellis, SJ; Bardonneau, C; Zijlstra, EE; Soipei, P; Mutinda, B; Omollo, R; Kimutai, R; Omwalo, G; Wasunna, M; Tadesse, F; Alves, F; Strub-Wourgaft, N; Hailu, A; Alexander, N; Alvar, J
Journal:
PLoS neglected tropical diseases
Abstract:
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a lower dose of AmBisome with miltefosine would show acceptable efficacy at the end of treatment.
Publisher:
Public Library of Science
Issue Date:
17-Jan-2019
URI:
http://hdl.handle.net/10144/619327
DOI:
10.1371/journal.pntd.0006988
PubMed ID:
30653490
Submitted date:
2019-01-24
Language:
en
ISSN:
1935-2735
Appears in Collections:
Leishmaniasis/Kala Azar; Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorDiro, Een
dc.contributor.authorBlesson, Sen
dc.contributor.authorEdwards, Ten
dc.contributor.authorRitmeijer, Ken
dc.contributor.authorFikre, Hen
dc.contributor.authorAdmassu, Hen
dc.contributor.authorKibret, Aen
dc.contributor.authorEllis, SJen
dc.contributor.authorBardonneau, Cen
dc.contributor.authorZijlstra, EEen
dc.contributor.authorSoipei, Pen
dc.contributor.authorMutinda, Ben
dc.contributor.authorOmollo, Ren
dc.contributor.authorKimutai, Ren
dc.contributor.authorOmwalo, Gen
dc.contributor.authorWasunna, Men
dc.contributor.authorTadesse, Fen
dc.contributor.authorAlves, Fen
dc.contributor.authorStrub-Wourgaft, Nen
dc.contributor.authorHailu, Aen
dc.contributor.authorAlexander, Nen
dc.contributor.authorAlvar, Jen
dc.date.accessioned2019-01-26T17:15:05Z-
dc.date.available2019-01-26T17:15:05Z-
dc.date.issued2019-01-17-
dc.date.submitted2019-01-24-
dc.identifier.citationA randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. 2019, 13 (1):e0006988 PLoS Negl Trop Disen
dc.identifier.issn1935-2735-
dc.identifier.pmid30653490-
dc.identifier.doi10.1371/journal.pntd.0006988-
dc.identifier.urihttp://hdl.handle.net/10144/619327-
dc.description.abstractVisceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a lower dose of AmBisome with miltefosine would show acceptable efficacy at the end of treatment.en
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen
dc.titleA Randomized Trial of AmBisome Monotherapy and AmBisome and Miltefosine Combination to Treat Visceral leishmaniasis in HIV Co-infected Patients in Ethiopiaen
dc.identifier.journalPLoS neglected tropical diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.